press-releases

 Mar 07, 2023, 16:05 ET  –  Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET –  Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif., March 7, 2023 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a […]

 Feb 28, 2023, 18:07 ET  CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023. Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific

 Feb 03, 2023, 17:17 ET  CUPERTINO, Calif., Feb. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and

 Nov 28, 2022, 18:46 ET  CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT’s board of directors today determined that the Company will effect a reverse stock split at a

 Nov 02, 2022, 16:05 ET  –  Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET –  AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update. “We are

 Oct 26, 2022, 08:30 ET  CUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022. Wednesday, November 2 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:

 Oct 06, 2022, 08:30 ET  AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif., Oct. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced

 Sep 26, 2022, 08:30 ET  POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR ATHLONE,

 Sep 06, 2022, 08:00 ET  CUPERTINO, Calif., Sept. 6, 2022 /PRNewswire/ — DURECT Corporation ( Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference.  Presentation details are as follows: H.C. Wainwright Global Investment Conference Date:           

 Aug 04, 2022, 16:05 ET  –  Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET –  Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif., Aug. 4, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update. “We continue to